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peripheral neuropathy (17.94 vs. 11.66, p=0.088) and lymphedema 
scores was observed (10 vs. 1.66, p=0.06).  
Twenty three patients who completed 6 months since IMRT, 
demonstrated improvement in physical and emotional function and 
significant decrease in symptom scales (p< 0.05) except insomnia 
score (p=0.276). On evaluation of cervix specific module, no 
difference was observed in functional scores as compared to baseline. 
However,an improvement in body image perception (81.31 vs. 97.47, 
p=0.009) and significant decrease in peripheral neuropathy (p= 0.014) 
was observed. Though reduction in global QoL was observed, but 
scores remained higher than baseline scores.(70.28 vs. 65.21 ).  
Conclusions: Patients with cervical cancer have higher QOL scores at 
6 months after completing adjuvant IMRT than at baseline. However 
this effect needs to be confirmed at further follow up and a larger 
cohort of patients undergoing IMRT.  
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Purpose/Objective: Survivors of Hodgkin’s Lymphoma (HL) are at risk 
of secondary tumors. None of the studies of secondary cancers in HL 
survivors have focused on the risk of developing skin cancers. We 
investigated the risk of developing secondary skin cancers after 
radiation therapy for HL, both in comparison to treatment without 
radiotherapy and to an age-matched Dutch population. 
Materials and Methods: We conducted a retrospective cohort study of 
889 HL patients treated between 1965 and 2005. Data on diagnosis of 
secondary skin cancers were collected by linkage with the nationwide 
pathology database. Data on treatment fields were extracted from 
patient files. Incidence rates of skin cancers and of basal cell 
carcinoma (BCC) specifically were compared to the expected number 
based on age, sex- and calendar period-specific incidence rates in the 
Dutch population. 
Results: 318 skin cancers were diagnosed in 86 patients. The majority 
of skin cancers (93%) were BCC. The standardized incidence ratio (SIR) 
of BCC in HL survivors was significantly increased compared to the 
general population (SIR 5.2, 95% CI 4.0-6.6), especially in the group 
aged <35 years at diagnosis (SIR 8.0, 95% CI 5.8-10.7). SIR increased 
with longer follow-up; after 35 years the SIR was 15.9 (95% CI 9.1-
25.9), with 626 excess cases per 10.000 patients per year. The risk of 
skin cancer was significantly increased in patients treated with 
radiotherapy (as part of) their treatment in comparison to patients 
treated with chemotherapy alone (HR 2.75, 95% CI 1.01-7.45, 
p=0.047). 
The majority of skin cancers developed within the radiation treatment 
fields (57%). Of the skin cancers that developed outside radiotherapy 
field 15% were located in near proximity of the radiation field 
borders. 
Conclusions: Radiotherapy for HL is associated with a strongly 
increased long-term risk of developing skin cancer, both in comparison 
to the general Dutch population and to treatment with chemotherapy 
alone. Since risks increase with longer follow-up, the total number of 
skin cancers in HL survivors is expected to further increase, 
implicating a substantial and clinically relevant problem. Patients and 
health care providers should be aware of this risk, in order to 
facilitate preventive measured and rapid access to early diagnosis and 
treatment. 
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Purpose/Objective: The standard treatment today is maximal surgical 
resection followed by concomitant chemo-radiation therapy followed 
by adjuvant TMZ , with median overall survival of 14.6 months and 2-
year survival rate of 26.5%. Despite the progress in neurosurgery, 
radiotherapy and oncology, the prognosis still result poor. In order to 
reduce the long time of standard treatment, in our institute we 
investigated the effects of hypofractionated radiation therapy (HFRT). 
For comparison, a group of 25 patients with similar characteristics and 
treated with Stupp protocol was retrospectively selected.  
Materials and Methods: 67 patients affected by GBL underwent 
surgical resection were treated between October 2005 and December 
2011 with HFRT followed or not by adjuvant chemotherapy with 
temozolomide (6-12 cycles). HFRT (5 Gy/fraction/day) was delivered 
to a total dose of 25 Gy in 5 fractions, dose prescribed at the 70% 
isodose. All patients received a non-contrast CT scan and MRI for 
treatment planning. After image fusion, the target volume was 
defined by the contrast-enhanced tumour edges on axial T1 and FLAIR 
sequences by consensus agreement of the neurosurgeon, 
neuroradiologist, and radiation oncologist. Treatment planning was 
performed to cover the 100% of planning target volume by 25 Gy, with 
maximum dose of 35.7 Gy. For treatment delivery, all patients 
received an portal image prior to each treatment fraction. Sex, age, 
type of surgery, Karnofsky performance status, Recursive Partitioning 
Analysis (RPA) classification, time between surgery and initiation of 
radiotherapy were analyzed as potential prognostic factors for survival 
using the univariate log-rank method.  
Results: All patients have completed the treatment protocol. Median 
age was 64,5 years (range 41-82 yrs) with 31 females (46%) and 36 
males (54%). Median KPS at time of treatment was 80. The surgery 
was gross total in 38 patients and subtotal in 14 patients; 15 patients 
underwent only biopsy. The patients characteristics of the two groups 
of patients are similar. With mean follow-up of 14.9 months (range 3-
62 months), the median overall survival and median progression- free 
survival were 12.43 and 6.9 months, respectively. No grade 3-4 acute 
or late neurotoxicity was observed. Post-treatment median KPS was 90 
(range 70-100). The overall tolerance of patients to HFRT was not 
different from that for conventional radiotherapy. Not statistically 
significant difference in terms of overall survival between HFRT group 
and Stupp protocol group was reported (p 0.12). 
Conclusions: The HFRT can be used for patients with GBL , resulting 
in favourable overall survival, low rates of toxicity and satisfying QoL. 
Future investigations are needed to determine the optimal 
fractionation for GBL. 
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Purpose/Objective: There is no established therapy for meningiomas 
that recur after surgery and radiotherapy. We carried out a pilot study 
to establish the tolerability and therapeutic potential of 177Lu-
DOTATATE(DOTA) which targets somatostatin receptors (sstr). 
Materials and Methods: 6 patients with recurrent progressive G2 
meningioma underwent 68Ga-DOTA PET/CT to assess eligibility for 
treatment (tx). 4 cycles of 7.4GBq 177Lu-DOTA were planned at 8-10 
week intervals.  
Protocol: antiemetic, cationic amino acid infusion to prevent renal 
toxicity (25g lysine/25g arginine in 1L of 0.9%NaCl over 4 hr), iv 
injection of 177Lu-DOTA (30 mins), short course of dexamethasone to 
prevent neuroaxial oedema, weekly full blood count monitoring for 6 
weeks. 
Metabolic activity was assessed on 68Ga-DOTA PET/CT prior to tx and 
at 1 year. Tumour size was evaluated on MRI by RECIST(1D) and WHO 
(2D) criteria and on a volumetric basis to establish a growth rate(GR) 
pre and post tx: GR= log10 (Vt/V0)/dt (exponential) and % growth per 
month (linear). 
Dosimetry was performed on cycle 2 for 1 patient. Post-tx whole body 
imaging and SPECT/CT was performed at 2.2,4.8, 21.4 and 92.6 hrs. 
Tumour volume was defined with contrast-enhanced CT at 21.4 hrs. 
Using a phantom derived SPECT sensitivity factor, the activity in the 
tumour at each time point was determined and a biexponential fitted 
to the time-activity curve. Accumulated activity was multiplied by the 
relevant s-factor determined for a spherical mass calculated from the 
tumour volume.  
Results: All 6 patients had sstr +ve disease and commenced tx. 4 
patients completed 4 cycles with minimal toxicity(G1 fatigue and G1 
thrombocytopenia in 1 patient). Median administered dose was 
7.4GBq, median interval 10 weeks. An overnight stay was required for 
radiation protection. 2 patients demonstrated symptom improvement 
(reduced seizures,improved muscle power). 2 patients stopped after 1 
